U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
139594
Substance Class Protein
Created
by admin
on Sat Dec 16 11:48:23 UTC 2023
Edited
by admin
on Sat Dec 16 11:48:23 UTC 2023
Protein Sub Type
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
19GBD6T9L7
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
D(2) DOPAMINE RECEPTOR
Common Name English
D2
Common Name English
DRD2
Common Name English
D2R
Common Name English
DRD2L
Common Name English
D2(LONG)
Common Name English
DOPAMINE D2 RECEPTOR
Common Name English
Code System Code Type Description
UNIPROT
P14416
Created by admin on Sat Dec 16 11:48:30 UTC 2023 , Edited by admin on Sat Dec 16 11:48:30 UTC 2023
PRIMARY
PHAROS
P14416
Created by admin on Sat Dec 16 11:48:30 UTC 2023 , Edited by admin on Sat Dec 16 11:48:30 UTC 2023
PRIMARY
FDA UNII
19GBD6T9L7
Created by admin on Sat Dec 16 11:48:30 UTC 2023 , Edited by admin on Sat Dec 16 11:48:30 UTC 2023
PRIMARY
From To
1_107 1_182
1_399 1_401
Glycosylation Type HUMAN
Glycosylation Link Type Site
N 1_5
N 1_17
N 1_23
Related Record Type Details
Structure of SPIPERONE H-3
RADIOLIGAND->TARGET
Structure of SUMANIROLE
AGONIST -> TARGET
Structure of LUMATEPERONE
ANTAGONIST->TARGET
BINDING
Ki
Structure of ABAPERIDONE
INHIBITOR -> TARGET
Structure of APLINDORE
PARTIAL AGONIST->TARGET
Structure of PERPHENAZINE
INHIBITOR -> TARGET
Structure of ARMODAFINIL
INHIBITOR -> TARGET
Structure of CQA-206-291
AGONIST -> TARGET
Structure of BROMPERIDOL
INHIBITOR -> TARGET
Ki
Structure of ONZIGOLIDE
AGONIST -> TARGET
Structure of F-17464 FREE BASE
INHIBITOR -> TARGET
Ki
Structure of BREXPIPRAZOLE
PARTIAL AGONIST->TARGET
Structure of PNU-142774E
AGONIST -> TARGET
Structure of RISPERIDONE
INHIBITOR -> TARGET
INHIBITOR
Ki
Structure of ZICRONAPINE
INHIBITOR -> TARGET
Structure of MBL C-11
RADIOLIGAND->TARGET
Ki
Structure of DESMETHOXYFALLYPRIDE
INHIBITOR -> TARGET
ANTAGONIST
Structure of ADOPRAZINE
INHIBITOR -> TARGET
Structure of NARONAPRIDE
INHIBITOR -> TARGET
Structure of 6-FLUORO-DMT
AGONIST -> TARGET
Structure of ISOREMOXIPRIDE
LIGAND->TARGET
Structure of PEROSPIRONE
INHIBITOR -> TARGET
Structure of ORDOPIDINE
INHIBITOR -> TARGET
Structure of QUINELORANE
AGONIST -> TARGET
Structure of CLOZAPINE
INHIBITOR -> TARGET
Ki
Structure of PALIPERIDONE
INHIBITOR -> TARGET
INHIBITOR
Ki
Structure of BIFEPRUNOX
PARTIAL AGONIST->TARGET
Structure of LURASIDONE
INHIBITOR -> TARGET
cell:CHO K1; ligand:3H-spiperone
Ki
Structure of PERGOLIDE
AGONIST -> TARGET
Structure of QUETIAPINE
INHIBITOR -> TARGET
Ki
Structure of BRILAROXAZINE
PARTIAL AGONIST->TARGET
Structure of ARIPIPRAZOLE
PARTIAL AGONIST->TARGET
Primary target for antipsychotic activity. The partial agonist actions of aripiprazole vary widely depending upon the cellular milieu. Thus, nearly fullagonism, weak partial agonism and frank antagonism, have all been reported, depending upon the assay system and cellular background.
Ki
Structure of PIRIBEDIL
AGONIST -> TARGET
Structure of 7-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN
INHIBITOR -> TARGET
BINDING
IC50
Structure of PROMAZINE
INHIBITOR -> TARGET
Structure of OSU-6162
PARTIAL AGONIST->TARGET
Structure of CABERGOLINE
AGONIST -> TARGET
Structure of SALVINORIN A
PARTIAL AGONIST->TARGET
Structure of THIOTHIXENE
INHIBITOR -> TARGET
Structure of 1-(3-Chlorophenyl)-4-(2-phenylethyl)piperazine
LIGAND->TARGET
Structure of DOPAMINE
AGONIST -> TARGET
D2R concentration levels were significantly lower in AD patients than in healthy controls (SMD = −1.13, 95%CI: −1.52 to −0.74), with low heterogeneity (I2 = 7.80%), when USA studies were considered.
Structure of PIMOZIDE
INHIBITOR -> TARGET
Structure of BROMOCRIPTINE
AGONIST -> TARGET
Structure of ILOPERIDONE
INHIBITOR -> TARGET
MAJOR
Ki
Structure of LIREXAPRIDE
AGONIST -> TARGET
Structure of APOMORPHINE
AGONIST -> TARGET
D2S Primary receptor interaction.. Emax 79%
EC50
Structure of CARIPRAZINE
PARTIAL AGONIST->TARGET
Structure of Dordaviprone
INHIBITOR -> TARGET
ANTAGONIST
Structure of BUTACLAMOL
INHIBITOR -> TARGET
Binding Assay
IC50
Structure of 7-OH-DPAT H-3
RADIOLIGAND->TARGET
Kd
Structure of ASENAPINE
INHIBITOR -> TARGET
Ki
Structure of SSR-181507
INHIBITOR -> TARGET
Structure of MAFOPRAZINE
INHIBITOR -> TARGET
Structure of ACEPROMAZINE
INHIBITOR -> TARGET
Structure of SUNEPITRON
AGONIST -> TARGET
Structure of ARAMISULPRIDE
INHIBITOR -> TARGET
Structure of IOLOPRIDE I-123
RADIOLIGAND->TARGET
Structure of CI-1007
AGONIST -> TARGET
PARTIAL AGONIST
Structure of OCAPERIDONE
INHIBITOR -> TARGET
Structure of ONC-206
INHIBITOR -> TARGET
Structure of TRIFLUOPERAZINE
INHIBITOR -> TARGET
Structure of SB-773812
INHIBITOR -> TARGET
Structure of ESAMISULPRIDE
INHIBITOR -> TARGET
Structure of RACLOPRIDE C-11
RADIOLIGAND->TARGET
Co-incubation with a D2L-dopamine receptor sub-saturating concentration of raclopride produced an apparent decrease in the equilibrium dissociation constant of the radioligand (i.e. KD = 6.0 nm vs. 1.9 nm
NON-COMPETITIVE
Kd
Structure of R-167154
INHIBITOR -> TARGET
Structure of TERGURIDE
PARTIAL AGONIST->TARGET
Ki
Structure of DINOXYLINE
AGONIST -> TARGET
Structure of BLONANSERIN
INHIBITOR -> TARGET
Structure of SARIZOTAN
INHIBITOR -> TARGET
Structure of ROXINDOLE
PARTIAL AGONIST->TARGET
Structure of BUSPIRONE
INHIBITOR -> TARGET
Structure of TALIPEXOLE
AGONIST -> TARGET
Structure of RACLOPRIDE
INHIBITOR -> TARGET
Ki
Structure of QUINPIROLE
AGONIST -> TARGET
Structure of AMISULPRIDE
ANTAGONIST->TARGET
SELECTIVE
Structure of SERTINDOLE
INHIBITOR -> TARGET
Structure of HALOPERIDOL
INVERSE AGONIST->TARGET
Ki
Structure of TRAZPIROBEN
INHIBITOR -> TARGET
Structure of FALLYPRIDE F-18
RADIOLIGAND->TARGET
Structure of HALOPERIDOL
AGONIST -> TARGET
BINDING
IC50
Structure of METOPIMAZINE
INHIBITOR -> TARGET
Structure of CHLORPROMAZINE
INHIBITOR -> TARGET
Structure of CYANODOTHIEPIN
LIGAND->TARGET
Structure of LYSERGIDE
LIGAND->OFF TARGET
BINDING
Ki
Structure of ZIPRASIDONE
INHIBITOR -> TARGET
Structure of SIBENADET
AGONIST -> TARGET
Structure of ROPINIROLE
AGONIST -> TARGET
Structure of PARDOPRUNOX
PARTIAL AGONIST->TARGET
Structure of NOLOMIROLE
AGONIST -> TARGET
Structure of SPIPERONE
INHIBITOR -> TARGET
BINDING
IC50
Structure of PRAMIPEXOLE
AGONIST -> TARGET
Structure of ROTIGOTINE
AGONIST -> TARGET
Structure of LENSIPRAZINE
INHIBITOR -> TARGET
Structure of 6-(2-(4-(BENZO(D)ISOTHIAZOL-3-YL)PIPERAZIN-1-YL)ETHYL)-4,4,8-TRIMETHYL-3,4-DIHYDRO-1H-QUINOLIN-2-ONE
INHIBITOR -> TARGET
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966